
F44-A13

Cat. No.:	HY-163436
CAS No.:	1338190-14-9
Molecular Formula:	C ₂₈ H ₄₀ N ₄ O ₅ S
Molecular Weight:	544.71
Target:	Cytochrome P450; FXR; RAR/RXR; PPAR; ROR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor; Cell Cycle/DNA
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



Product Data Sheet



Concentration:	F44-A13: 3, 10, 30 μM; CDCA: 100 μM
Incubation Time:	24h
Result:	Was able to reverse the regulation of FXR downstream target genes Shp, Bsep and Cyp7a by CDCA in a dose-dependent manner.
	Decreased the expression level of Shp and Bsep, and increased the expression level of
	Cyp7a1.

In Vivo

F44-A13 (20, 40 mg/kg; Oral gavage (p.o.) and Intraperitoneal injection (i.p.); 4 days) effectively reduces the levels of TC, TG and LDL-C in a C57BL/6 mice model^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice ^[1]
Dosage:	20, 40 mg/kg
Administration:	Intraperitoneal injection (i.p.) and Oral gavage (p.o.); 4 days
Result:	Intraperitoneal injection significantly reduced TC levels by more than 28%, and oral administration significantly reduced TC levels in a dose-dependent manner. Reduced TG levels by more than 30% at both 20 and 40 mg/kg orally, while intraperitoneal injection did not significantly reduce TG levels. Oral doses of 20 and 40 mg/kg were effective in reducing LDL-C levels by 12% and 23%, and intraperitoneal injections by 38%.

REFERENCES

[1]. Dou X, et al. Discovery of novel and selective farnesoid X receptor antagonists through structure-based virtual screening, preliminary structure-activity relationship study, and biological evaluation. Eur J Med Chem. 2024;269:116323.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA